Skip to main content
OpenTrials
Completed

NCT Number: NCT03241498

General Practitioner (GP) Practice Based Pharmacist Input to Medicines Optimisation

The study is a United Kingdom (UK) based multi-centre study which will evaluate the impact of a medication optimisation intervention (delivered in GP practices by pharmacists to patients at risk of medication related problems), on healthcare resource utilisation and patient outcomes. Pharmacists in 4 areas across the UK (3 in England and 1 in Northern Ireland) will engage with patients, thought to be at a higher risk of medication related problems, within their GP practice in order to help identify areas for improvement

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Northern Health and Social Care Trust

Antrim, Northern Ireland, United Kingdom

About this study

Drug therapy is growing more complex as patients increasingly suffer from a number of co-morbidities. Accordingly, in clinical medicine, a wide range of medication related problems may arise (1). A medication related problem (MRP) is defined as "an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes" (2). These problems have been found to lead to more hospital admissions and thus increase the cost of healthcare provision (3, 4). For instance, Winterstein et al. carried out a meta-analysis of research in this area which showed that 7.1% of hospital admissions were attributable to a drug related problem, of which 59% appeared avoidable (5). Moreover, a large study in the United Kingdom showed that these admissions cost the National Health Service (NHS) up to £466 million annually, which is 0.59% of the British health care budget (6).

Medication related problems (MRPs) remain a serious concern particularly in primary care settings. A recent UK study found that one in 20 prescription items in general practice included an error, affecting 1 in 8 patients. Although the majority of these errors were described as being either mild or moderate in severity, 1 in 550 of all prescription items contained an error determined to be severe (7). In addition, significant medication wastage has been found within general practice settings in England with an estimated £300 million worth of prescribed medications being wasted each year in primary and community care (8). Optimisation of drug therapy and prevention of MRPs can reduce health care expenditure, potentially save lives and enhance patient quality of life (9-13).

Medicines optimisation is defined as 'a person-centred approach to safe and effective medicines use, to ensure people obtain the best possible outcomes from their medicines. Medicines optimisation applies to people who may or may not take their medicines effectively. Shared decision-making is an essential part of evidence-based medicine, seeking to use the best available evidence to guide decisions about the care of the individual patient, taking into account their needs, preferences and values' (14, 15, 16).

Medicines optimisation requires more patient engagement and professional collaboration within health and social care settings. It focuses on actions taken by all health and social care practitioners. To support the medicines optimisation agenda a guide on medicines optimisation has been produced by The Royal Pharmaceutical Society (RPS) the aim of which is to help patients make the most of their medicines (17). This guide involves four key principles for medicines optimisation in order to achieve improved patient outcomes (16). These principles are as follows:

(i) Aim to understand the patient's experience (ii) Evidence based choice of medicines (iii) Ensure medicines use is as safe as possible (iv) Make medicines optimisation part of routine practice

In order to support the implementation of the guiding principles, NHS England launched the prototype medicines optimisation dashboard in 2014. The dashboard aims to 'encourage Clinical Commissioning Groups (CCGs) and healthcare Trusts to think more about how well their patients are supported to use medicines and less about focusing on cost and volume of drugs' (16).

Primary care systems have started utilising a team based approach to care delivery. Pharmacists have been increasingly recognised as a part of the healthcare professional team within primary care settings in many countries (18). This integration of pharmacists into primary health care systems was found to have significant benefits that included reduction of errors, effective identification and resolution of medication related problems, improvements in medication adherence, improved patient outcomes, relief of work pressure on GPs, improved communication and cooperation between health professionals, and strengthened team working within primary care (18-22).

Despite the expansion of the role of pharmacists in the primary health care setting, limited research has been conducted to evaluate the impact of pharmacist input on health service utilisation and cost.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients are included in the study if they have any of the following:

  • Have had at least 1 unplanned hospital admission or 2 or more accident and emergency department (A&E) attendances in the previous 12 months.
  • Prescribed ≥ 6 regular oral/systemic, long term medicines.
  • Has ≥ 2 long-term chronic conditions.

Exclusion criteria

  • Patient is residing in a nursing home or a care home.
  • Patient is considered unable to give written informed consent e.g. Alzheimer's disease.
  • Palliative care patients.
  • Patient has had ≥ 4 unplanned admissions to hospital in the previous 6 months.
  • Patient is participating in another intervention research project within the practice.

Treatment and study plan

Medicines optimisation

Other

Primary outcomes

  1. Number of unplanned hospital admissions

    Time frame: Recruitment - 6 months post intervention

    Number of unplanned admissions to hospital over the follow-up period will be collected for both control and intervention patients

  2. Number of A&E attendances

    Time frame: Recruitment - 6 months post intervention

    Number of attendance to the A&E department over the follow-up period will be collected for both control and intervention patients

  3. Number of GP consultations

    Time frame: Recruitment - 6 months post intervention

    Number of unplanned consultations with the patient's GP over the follow-up period will be collected for both control and intervention patients

Secondary outcomes

  1. Medication appropriateness index (MAI) score

    Time frame: Recruitment - 6 months post intervention

    MAI scores will be calculated at the beginning and end of the project for each patient recruited into the study

  2. Number of medication related problems

    Time frame: Recruitment - 6 months post intervention

    Number of medication related problems will be calculated at the beginning and end of the project for each patient recruited into the study

  3. Health-related quality of life (HRQOL)

    Time frame: Recruitment - 6 months post intervention

    HRQOL scores will be calculated using the EQ-5D tool at the beginning and end of the project for each patient recruited into the study

  4. Medication Adherence report scale (MARS)

    Time frame: Recruitment - 6 months post intervention

    MARS scores will be calculated at the beginning and end of the project for each patient recruited into the study

  5. Beliefs about medicines questionnaire (BMQ)

    Time frame: Recruitment - 6 months post intervention

    BMQ scores will be calculated at the beginning and end of the project for each patient recruited into the study

  6. Patient satisfaction with GP services

    Time frame: Recruitment - 6 months post intervention

    Patients will be asked to complete a bespoke satisfaction questionnaire in order to assess their satisfaction with the new service which has been provided

  7. Patient laboratory data relevant to medications being received

    Time frame: Recruitment - 6 months post intervention

    Pertinent laboratory data will be collected throughout the intervention period and follow-up

Sponsors and collaborators

Lead sponsor

Queen's University, Belfast

Other

Collaborators

  • Association of the British Pharmaceutical Industry (ABPI)
  • Medicines Optimisation Innovation Centre (MOIC)

Registry information

Official study title

GP Practice Based Pharmacist Input to Medicines Optimisation

Important dates

Study start
2016
Primary completion
2018
Study completion
2019
First posted
Aug 7, 2017
Registry last updated
Dec 17, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.